By Katherine Hamilton

DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial.

The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group.

Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied.

DBV enrolled 654 children aged 4 to 7 years in the trial.

The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year.

The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 16, 2025 16:23 ET (21:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.